Zometa did not appear to prevent breast cancer from returning or to boost disease-free survival overall. Medicynical Note: This drug costs in the range of $1000/month.
Aromatase inhibitors appear to increase the risk of cardiac events among women being treated for breast cancer, an analysis of several studies showed.
The relative risk of suffering a cardiovascular event increased 26% (P≤0.01); however, that excess risk can be mitigated if a woman is treated with tamoxifen first and then switches to an aromatase inhibitor, according to Eitan Amir, MD, of the Princess Margaret Hospital in Toronto.
Medicynical Note: Those opposing such studies claim they are tantamount to having “death panels.” Such studies they say would restrict access to treatments.
On the other hand authorizing use of drugs that are expensive and do no good, or even do harm is criminal, given our expensive non-system of care.
Lastly it should be pointed out that there is no bar to people paying for drugs themselves if their insurer refuses payment.